Why Human Genome Shares Doubled
Apr 19th 2012 12:15PM
Updated Apr 19th 2012 12:16PM
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: Glaxo's offer values Human Genome at $13 per share and represents a whopping 81% premium to its Wednesday closing price. However, Human Genome's board rejected the offer as inadequate, fueling investor hopes of an even higher bid.
Now what: Human Genome said it has hired Goldman Sachs and Credit Suisse to help with the exploration of alternative strategies, which includes a possible sale of the company. Of course, the purchase of Human Genome would give Glaxo full rights to their partnered drugs and generate a whopping $200 million in cost synergies within a couple of years, so there's a good chance that Glaxo will indeed pay up to get the deal done. For lucky Human Genome shareholders waking up to today's whopping 100% gain, though, taking at least some dough off the table still seems prudent.
Interested in more info on Human Genome? Add it to your watchlist.
At the time this article was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline and Goldman Sachs. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.